Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp. (NASDAQ: TNXP) CEO Dr. Seth Lederman tells Proactive why the clinical-stage biopharmaceutical company had decided to stop enrollment in its Phase 3 RALLY study of TNX-102 SL to treat fibromyalgia.
In addition, Dr. Lederman discussed the group's intent to acquire a 48,000 square foot infectious disease R&D Facility in Frederick, Maryland, to help the expand its infectious disease pipeline.